Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Por:
Genesca, E, Morgades, M, Gonzalez-Gil, C, Fuster-Tormo, F, Haferlach, C, Meggendorfer, M, Montesinos, P, Barba, P, Gil, C, Coll, R, Moreno, MJ, Martinez-Carballeira, D, Garcia-Cadenas, I, Vives, S, Ribera, J, Gonzalez-Campos, J, Diaz-Beya, M, Mercadal, S, Artola, MT, Cladera, A, Tormo, M, Bermudez, A, Vall-llovera, F, Martinez-Sanchez, P, Amigo, ML, Monsalvo, S, Novo, A, Cervera, M, Garcia-Guinon, A, Ciudad, J, Cervera, J, Hernandez-Rivas, JM, Granada, I, Haferlach, T, Orfao, A, Sole, F, Ribera, JM
Publicada:
1 oct 2021
Ahead of Print:
1 jun 2021
Resumen:
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of >3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with >3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corre-sponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying kar-yotypes with >3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), inde-pendently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Addi-tional molecular analyses of patients carrying >3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel tar-geted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
Filiaciones:
Genesca, E:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
Morgades, M:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
ICO Hosp Germans Trias & Pujol, Dept Clin Hematol, Badalona, Spain
Gonzalez-Gil, C:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
Fuster-Tormo, F:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
Haferlach, C:
MLL Munich Leukemia Lab, Munich, Germany
Meggendorfer, M:
MLL Munich Leukemia Lab, Munich, Germany
Montesinos, P:
Inst Carlos III, Hosp Univ Politecn La Fe, Madrid, Spain
Inst Carlos III, CIBERONC, Madrid, Spain
Barba, P:
Hosp Univ Vall dHebron, Clin Hematol Serv, Barcelona, Spain
Gil, C:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
Hosp Gen Alicante, Clin Hematol Serv, Alicante, Spain
Coll, R:
Hosp Josep Trueta ICO, Clin Hematol Serv, Girona, Spain
Moreno, MJ:
Hosp Virgen de la Victoria, Clin Hematol Serv, Malaga, Spain
Martinez-Carballeira, D:
Hosp Univ Cent Asturias, Clin Hematol Serv, Oviedo, Spain
Garcia-Cadenas, I:
Hosp Santa Creu & Sant Pau, Clin Hematol Serv, Barcelona, Spain
Vives, S:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
ICO Hosp Germans Trias & Pujol, Dept Clin Hematol, Badalona, Spain
Ribera, J:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
ICO Hosp Germans Trias & Pujol, Dept Clin Hematol, Badalona, Spain
Gonzalez-Campos, J:
Hosp Virgen del Rocio, Clin Hematol Serv, Seville, Spain
Diaz-Beya, M:
Hosp Clin Barcelona, Clin Hematol Serv, Barcelona, Spain
Mercadal, S:
Hosp Duran & Reynals ICO, Clin Hematol Serv, Lhospitalet De Llobregat, Spain
Artola, MT:
Hosp Univ Donostia, Clin Hematol Serv, Donostia San Sebastian, Spain
Cladera, A:
Hosp Son Llatzer, Clin Hematol Serv, Palma De Mallorca, Spain
Tormo, M:
Hosp Clin Valencia, Clin Hematol Serv, Valencia, Spain
Bermudez, A:
Hosp Marques de Valdecilla, Clin Hematol Serv, Santander, Spain
Vall-llovera, F:
Hosp Mutua Terrassa, Clin Hematol Serv, Terrassa, Spain
Martinez-Sanchez, P:
Hosp 12 Octubre, Clin Hematol Serv, Madrid, Spain
Amigo, ML:
Hosp Morales Meseguer, Clin Hematol Serv, Murcia, Spain
Monsalvo, S:
Hosp Gregorio Maranon, Clin Hematol Serv, Madrid, Spain
Novo, A:
Hosp Son Espases, Clin Hematol Serv, Palma De Mallorca, Spain
Cervera, M:
Hosp Joan 23, Clin Hematol Serv, Tarragona, Spain
Garcia-Guinon, A:
Hosp Arnau Vilanova, Clin Hematol Serv, Lleida, Spain
Ciudad, J:
Hosp Clin Univ Salamanca HUS, Ctr Invest Canc IBMCC CSIC USAL CIC, Inst Biosanitario Salamanca IBSAL, CIBERONC, Salamanca, Spain
Cervera, J:
Inst Carlos III, Hosp Univ Politecn La Fe, Madrid, Spain
Inst Carlos III, CIBERONC, Madrid, Spain
Hernandez-Rivas, JM:
Hosp Clin Univ Salamanca HUS, Inst Biol Mol & Celular Canc IBMCC, Ctr Invest Canc CIC, Salamanca, Spain
Granada, I:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
ICO Hosp Germans Trias & Pujol, Dept Clin Hematol, Badalona, Spain
Haferlach, T:
MLL Munich Leukemia Lab, Munich, Germany
Orfao, A:
Hosp Clin Univ Salamanca HUS, Ctr Invest Canc IBMCC CSIC USAL CIC, Inst Biosanitario Salamanca IBSAL, CIBERONC, Salamanca, Spain
Sole, F:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
Ribera, JM:
Univ Autonoma Barcelona UAB, Josep Carreras Leukaemia Res Inst IJC, Campus ICO Hosp Germans Trias & Pujol, Badalona, Spain
ICO Hosp Germans Trias & Pujol, Dept Clin Hematol, Badalona, Spain
hybrid, Green Published
|